Research Paper Volume 16, Issue 17 pp 12392—12413
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway
Figure 6. The expression of RPL22L1 was related to immune infiltration in LUAD single cells.